Looking at the filing, I can confirm this is REGENXBIO Inc.'s Form 10-Q for the quarterly period ended September 30, 2026, filed on NASDAQ under the ticker RGNX. The filing content provided is primarily the cover page, table of contents, and forward-looking statements section. I will extract all verifiable facts from this content.

REGENXBIO Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended September 30, 2026, disclosing share count, filing status, and key operational and regulatory risk factors as of November 5, 2026.

Key Highlights

  • Share count: As of October 30, 2026, REGENXBIO had 66,122,600 shares of common stock, par value $0.0001 per share, issued and outstanding.
  • Smaller reporting company: The company indicated it is classified as a non-accelerated filer and a smaller reporting company under SEC definitions.
  • AbbVie collaboration: The filing identifies a collaboration with AbbVie to develop and commercialize ABBV-RGX-314 (surabgene lomparvovec, also referred to as sura-vec) as a key operational factor.
  • Nippon Shinyaku collaboration: The filing also identifies a collaboration with Nippon Shinyaku Co., Ltd. to develop and commercialize RGX-121 (clemidsogene lanparvovec) and RGX-111.
  • Regulatory challenges: According to the filing, the company cited its ability to address deficiencies raised by the FDA regarding RGX-121 as part of a Complete Response Letter or subsequent clinical hold as a risk factor.
  • Clinical hold on RGX-111: The filing identifies resolution of a partial clinical hold for RGX-111 to the FDA's satisfaction as a material uncertainty.
  • Going concern flag: The filing lists "our ability to continue as a going concern" among its forward-looking risk factors.

REGENXBIO's Third-Quarter 2026 Disclosure: Regulatory Risk and Clinical Programs

REGENXBIO Inc., a gene therapy company headquartered at 9804 Medical Center Drive, Rockville, MD 20850, filed its quarterly report covering the three and nine months ended September 30, 2026. The company's common stock trades on The Nasdaq Global Select Market under the symbol RGNX (NASDAQ:RGNX). The filing confirms that as of October 30, 2026, the company had 66,122,600 shares of common stock issued and outstanding at a par value of $0.0001 per share.

According to the filing, REGENXBIO maintains two key external collaborations for its lead product candidates. The first is with AbbVie, covering the development and commercialization of ABBV-RGX-314, known by its non-proprietary name surabgene lomparvovec (sura-vec). The second is with Nippon Shinyaku Co., Ltd., covering RGX-121 (clemidsogene lanparvovec) and RGX-111. The filing identifies the ability to establish and maintain these partnerships as a forward-looking risk. All forward-looking statements in the filing are the company's own and are subject to its cautionary language regarding risks and uncertainties.

The filing specifically identifies regulatory risks tied to RGX-121, noting the company's need to address deficiencies raised by the FDA through a Complete Response Letter or a subsequent clinical hold. Additionally, a partial clinical hold on RGX-111 is cited as a pending matter requiring resolution to the FDA's satisfaction. The company also lists multiple active clinical trial programs by name, including AAVIATE, AFFINITY BEYOND, AFFINITY DUCHENNE, AFFINITY RISE, ALTITUDE, ASCENT, ATMOSPHERE, CAMPSIITE, and NAAVIGATE, among others. The filing further discloses that "our ability to continue as a going concern" is among the uncertainties the company faces, as stated in its forward-looking risk factors.

What Was Disclosed

REGENXBIO Inc. submitted its Form 10-Q for the quarterly period ended September 30, 2026, reporting 66,122,600 shares outstanding as of October 30, 2026, and disclosing regulatory risks tied to RGX-121 and RGX-111, along with active clinical trial programs and two external development collaborations.